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ABSTRACT OF THESIS

INTERACTION OF ISOFLAVONES AND ENDOPHYTE-INFECTED TALL FESCUE SEED EXTRACT
ON VASOACTIVITY OF BOVINE MESENTERIC VASCULATURE

Endophyte-infected tall fescue produces many ergot alkaloids, which have been shown
to be vasoconstrictive in various vessel types of bovine. On the other hand, substantial
evidence has been reported on the vasodilative effects of formononetin and biochanin A
in different vessel types in humans and rats. So, a study was conducted using mesenteric
vasculature collected from heifers shortly after slaughter. After 2-h incubation with
formononetin (F), biochanin A (B), or an ergovaline-containing tall fescue seed extract
(EXT) and their combinations, vessels were mounted in a multi-myograph to determine
their ergotamine-induced contractility. Results indicated that F and B at 1 × 10-6 M and
their combination did not impact the contractile response to ergotamine in mesenteric
vasculature. The pre-myograph incubation of mesenteric vasculature with EXT altered the
contractile response manner to ergotamine. However, at higher concentration, F and B
may alleviate the reduction of vasoconstriction caused by prior exposure to EXT. To our
knowledge, this study was the first to investigate the interaction of ergot alkaloids and
isoflavones on in vitro bovine mesenteric vasculature. However, further investigations are
necessary to understand the mechanism behind the interaction of ergot alkaloids and
isoflavones on vasoactivity.
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Chapter 1. Literature Review
Ergot Alkaloids
History
Ergot alkaloids have been playing important roles, as toxins and natural
pharmaceuticals, throughout human history. It has been speculated that ergot alkaloids
which induced hallucinations were the culprit four thousand years ago in the Eleusinian
Mysteries of ancient Greece (Wasson et al., 1978). Although used in obstetrics as early as
1100 B.C. for their medicinal effects (Schiff, 2006), poor understandings of their
physiological effects and toxicodynamics limited the beneficial uses of ergot alkaloids in
these early times.
During the Middle Ages, several bizarre epidemics outbroke in various medieval
European countries and killed thousands of people (Wasson et al., 1978; Schiff, 2006).
Those outbreaks are now understood and have been attributed to long-term ergot
poisoning, also termed as ergotism (Caporael, 1976). The cause of ergotism is indirect
ingestion of ergot alkaloids from ergot-contaminated grains (Strickland et al., 2011). Two
different forms of toxic symptoms were characterized from these ergotism outbreaks.
The first form was described as gangrenous form (Ergotismus gangraenosus) (Schiff,
2006), also referred to as “Holy fire”, or “St. Anthony’s fire”, which vividly portrays the
severe burning pain (“fire”) in the extremities (Wasson et al., 1978; Flieger et al., 1997;
Schiff, 2006). It is now obvious that prominent peripheral vasoconstriction initiated the

1

swelling and extreme burning pain of limbs, and eventually caused gangrene (Flieger et
al., 1997).
The second type of symptoms was called the convulsive form (Ergotismus
convulsivus) (Schiff, 2006). Persons with this type developed delirium and hallucinations
in Eleusinian Mysteries of ancient Greece as Wasson et al. (1978) speculated. However,
recent incidence of ergotism has been very scarce and results from the achievements in
agriculture in terms of genetics and management and on techniques of grain sanitization
which removes most of the sclerotia (Flieger et al., 1997).
With improved understanding of ergot alkaloids, their beneficial uses have been
discovered. Examples of their pharmacological effects include: cerebrovascular
insufficiency, prolactin inhibition, treatment of Parkinsonism, thrombosis, stimulation of
cerebral and peripheral metabolism, venous insufficiency, uterine stimulation, and as a
dopaminergic agonist (Aellig et al., 1978).
The first ergot alkaloids (ergotoxine, which later found to be a mixture of four
alkaloids) were isolated by G. Barger and H. Dale in 1906 (De Costa, 2002). Ergotamine,
as the first pure alkaloid, was isolated by Arthur Stoll in 1918 (Peroutka, 1996). Isolated
pure ergot alkaloids allowed researchers to have a closer look at their structures and
chemistry, which is highly beneficial for understanding and further exploitation of their
medical benefits. Nowadays, researchers are focusing on molecular, biological and
biochemical investigations in terms of ergot alkaloid biosynthesis (Wallwey and Li, 2011).
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Chemistry of Ergot Alkaloids
So far, approximately 50 natural ergot alkaloids have been characterized (Flieger
et al., 1997). The common structural feature of all ergot alkaloids is a tetracyclic ergoline
ring system (Figure 1.1) (Garner et al., 1993; Flieger et al., 1997; Schiff, 2006; Strickland
et al., 2011), with nitrogen methylated at the 6 position and carbon substituted variously
at 8 position. From a biosynthetic perspective, the indole moiety is derived from
tryptophan

(Bu'Lock

and

Barr,

1968).

Acetate

is

metabolized

to

dimethylallylpyrophosphate, which is found in many biological systems (Garner et al.,
1993). In many ergot alkaloids, a double bond usually exists between C-8 and C-9 or C-9
and C-10. The position of the double bond permits compounds to have epimers, which is
reported to not only have different sensitivities to temperature and solvents (Hafner et
al., 2008), but also differing biological potency in animal systems (Berde and Stürmer,
1978; Berde, 1980). Based on the different type of substitutes on C-8 of ergoline ring,
ergot alkaloids are classified into three groups: 1) clavine alkaloids, 2) lysergic acid and its
simple amides (derivatives), 3) ergopeptine alkaloids (Figure 1.2) (Lyons et al., 1986;
Porter, 1995; Schardl et al., 2006; Wallwey and Li, 2011). As shown in Figure 1.2, clavine
alkaloids generally are 6, 8-dimethylergolines with a few exceptions, such as chanoclavine,
which has a 6, 7-Seco ring. Lysergic acid is characterized as a substituted carboxyl group
on C-8 of ergoline ring. Amidation of the carboxyl group on C-8 derives the lysergic acid
amide (Schiff, 2006). Due to their high pharmacological activity, lysergic acid amide, such
as ergometrine and methylergometrine, have been used to prevent and treat postpartum
hemorrhage (De Costa, 2002; Rajan and Wing, 2010).
3

The third group, ergopeptine alkaloids, are structurally characterized as lysergic
acid derivatives with a tripeptide moiety attached to its carboxy group by peptide-like
amide bonds (Figure 1.3) (Wallwey and Li, 2011). Various substitutions at R1 and R2
accounts for the diversity of ergopeptine alkaloids (Table 1.1).
Among ergopeptines, ergovaline and ergotamine commonly draw more attention
of researchers. Lyons et al. (1986) reported that ergovaline was the predominant (84 to
97%) alkaloids of all the five detected ergopeptine alkaloids from tall fescue (Lolium.
arundinaceum) pasture. Both ergovaline and ergotamine are vasoconstrictive and
therefore have some therapeutically significant properties, especially ergotamine and its
derivatives which have been used as a therapy for vascular headaches, such as migraines
(Schiff, 2006). The structural similarities of ergoline ring to the biogenic amines, dopamine,
epinephrine, norepinephrine, serotonin, explains many of the biological effects of ergot
alkaloids at the cellular or molecular level (Weber, 1980). The “mistaken” recognition and
binding by biogenic amine receptors renders ergot alkaloids active in some of the
biological agonist roles. This is the pharmacological rationale of ergot alkaloids as they
are applied to treat rhage, migraine, venostasis, hyperprolactinemia and Parkinson’s
disease (Berde, 1980).
Natural Sources of Ergot Alkaloids
Naturally, ergot alkaloids are produced by fungal endophytes, mainly within the
Hypocreales and Eurotiales orders. Claviceps genus under Hypocreales order have been
known and parasitize more than 600 plants (Strickland et al., 2011). Claviceps sclerotia
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were also found in several important grains such as barley, wheat, rye, millet, and oats
(Bové, 1970; Groger, 1972), which was the major culprit of the ergotism outbreaks during
the Middle Ages in Europe.
Since Stoll first isolated and identified ergotamine from Claviceps sclerotia (Stoll,
1952), several other endophytic fungi genus such as Epichloë, Neotyphodium, and
Balansia, have been proven to produce ergot alkaloids on contaminated plants (Bacon,
1988; Flieger et al., 1997; Clay and Schardl, 2002). However, the production of ergot
alkaloids varies depending on the interactions of different fungi and plants. For example,
fungi Aspergillus and Penicillium possess a lower capability of producing ergot alkaloids
than Claviceps (Reshetilova and Kozlovskii, 1990; Flieger et al., 1997).
On the other hand, ergot alkaloids are distributed differently within the plant. For
instance, ergot alkaloid concentrations in tall fescue from high to low is generally seed,
crown, stems, leaves, and roots (Rottinghaus et al., 1991; Azevedo and Welty, 1995).
What’s more, environmental factors (growth temperature, humidity, soil fertility) also
play big roles in impacting the growth of certain fungi and further regulating the
production of ergot alkaloids. The symbiotic interactions between plants and endophytic
fungi benefit the host in terms of the greater resistance to insects, herbivores, pathogens,
as well as enhanced environmental tolerance and overall competitiveness. Even though
the endophyte infected grains are no longer an ergotism risk for humans, the ergot
alkaloids produced by these endophytes, especially Neotyphodium coenophialuminfected tall fescue (L. arundinaceum), hamper livestock production (Strickland et al.,
2011).
5

Fescue Toxicosis and Its Influence on Livestock
Tall fescue [Lolium arundinaceum (Schreb.) Darbysh.] is the most widely
distributed cool-season perennial pasture grass in the world. Although tall fescue is a
native of Europe, it has been distributed and cultivated in North and South America,
southern Africa, Australia, New Zealand, and eastern Asia (Hannaway et al., 2009). Tall
fescue is the predominant temperate pasture grass grown within the transition zone of
the eastern and central part of the United States (Strickland et al., 2009a), covering
approximately 15 million ha (Buckner et al., 1979).
With the wider occurrence and application of tall fescue in pastures, there were
reports of grazing animal having health problem and poor performance (Pratt and Haynes,
1950; Pratt and Davis, 1954). Following this, several grazing studies found gains of beef
steers on tall fescue were significantly lower than on orchardgrass (Dactylis glomerata L.)
(Blaser et al., 1956; Mott et al., 1971; Harris, 1972). Other than decreased bodyweight
gains and cow conception rates (Petritz et al., 1980), three major disorders have been
observed and characterized (Stuedemann and Hoveland, 1988).
Fescue foot is considered the most dramatic visible symptom which was first
reported by Cunningham (1949) in New Zealand. The incidence was usually higher in cold
weather with the signs: stiffness and soreness of tissue (dry gangrene) appearing near the
end of hoof or tail, lameness in hind quarters, loss of tail switch (Cunningham, 1949).
These disorders are similar with the symptoms of gangrenous form ergotism, which is
caused by the vasoconstrictive effect of ergot alkaloids on extremities.
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The other two symptoms, summer slump and fat necrosis, have been intensively
reviewed (Bush and Buckner, 1973; Strickland et al., 1993; Strickland et al., 2009a; Waller,
2009) and are characterized by reduced bodyweight gain, rough hair coat, elevated body
temperature and respiration rate, reduced milk production, lesser tolerance of heat. In
general, these three typical symptoms belong to a more comprehensive toxicity
syndrome, termed as tall fescue toxicosis (also known as fescue toxicosis) (Strickland et
al., 2009a).
The first conclusive evidence was unclear until Bacon et al. (1977) and coworkers
first reported that the presence of an endophytic fungi, Epichloë typhina, in tall fescue
which associated with fescue toxicosis. Later, this endophyte was renamed as
Acremonium coenophialum, and then Neotyphodium coenophialum (Morgan-Jones and
Gams, 1982). Unsurprisingly, the clavine alkaloids and lysergic acid amides (Porter et al.,
1981; Yates and Powell, 1988; Yates et al., 1989; Petroski and Powell, 1991), and
ergopeptine alkaloids (Yates et al., 1985; Lyons et al., 1986; Yates and Powell, 1988) were
all detected from Neotyphodium coenophialum-infected tall fescue.
In combination with the symptom similarity of fescue toxicosis and ergotism, ergot
alkaloids are most likely the causative agents of fescue toxicosis. As proved later by many
researchers, ungulates’ consumption of ergot alkaloids produced by Neotyphodium
coenophialum-infected tall fescue induces the fescue toxicosis, which is considered as the
main grass-induced toxicosis in the United States (Cheeke, 1995). Considering tall fescue’s
prevalence as pasture grass in the southeastern United States, it is self-evident that the
economic loss on livestock production of fescue toxicosis is profound. In United States,
7

the annual economic losses from decreased conception rates and weaning weights of
beef cattle grazing endophyte-infected tall fescue were conservatively estimated at $609
million (Hoveland, 1993). When taking into account the influences on the equine and
small ruminant industries, as well as calculations based on today’s dollars, the overall
annual losses are estimated to exceed 1 billion dollars (Strickland et al., 2011). Admittedly,
a comprehensive solution to fescue toxicosis has not been proposed so far, neither as a
systematic mechanism of ergot alkaloids on different physiology systems of domestic
animals. Nevertheless, a great deal of research has been and will be conducted to better
understand the toxicodynamics of fescue toxicosis and to further explain the complex
interaction among the animal, ergot alkaloids, plant, endophyte and environmental
factors involved (Strickland et al., 2011).
Toxicodynamics
Grazing endophyte-infected tall fescue induces several disorders of different
physiological systems (gastrointestinal, reproduction, cardiovascular, etc.) (Strickland et
al., 2011) which are summarized in general as fescue toxicosis. In terms of seeking more
comprehensive and effective solutions of fescue toxicosis, it is vital to thoroughly
understand the physiological mechanisms behind every fescue toxicosis induced disorder.
It has been intensively reviewed in regard to the impact of ergot alkaloids from toxic
endophyte-infected tall fescue on the animals microbial ecology, gastrointestinal system,
neural and

neuroendocrine

systems,

reproductive

system,

immune

system,

cardiovascular system, and the possible toxicodynamics associated with them (Strickland
et al., 2009a; Strickland et al., 2011). In this section, the major focus will be located on the
8

ergot alkaloids’ impact on cardiovascular system, especially on core or peripheral blood
vascular function and the potential mechanism behind them.
As mentioned previously, grazing endophyte-infected tall fescue results in major
impacts on vascular function, which leads to the symptoms of gangrene of extremities
and elevated body temperature. In support, research findings tend to favor ergot
alkaloids as the primary causative agents of fescue toxicosis (Solomons et al., 1989; Oliver
et al., 1992; Oliver et al., 1993; Strickland et al., 1996; Oliver et al., 1998; Klotz et al., 2006;
Klotz et al., 2007), especially in consideration of their biological activities on blood vessels.
Two primary effects of ergot alkaloids on cardiovascular systems of domestic animals
have been summarized (Strickland et al., 2011). First, immediate reduction of heart rate
appears at 4 hours after E+ tall fescue consumption, and gradually returns back to preexposure level in about 172 hours (McLeay et al., 2002; Aiken et al., 2007; Aiken et al.,
2009). Second, vasoconstriction and possible morphological changes (such as smooth
muscle cell hyperplasia and endothelial cell damage) of blood vessels (Rhodes et al., 1991;
Strickland et al., 1996; Oliver and Schultze, 1997; Shappell, 2003; Aiken et al., 2007; Aiken
et al., 2009). This section will mainly focus on the effects of ergot alkaloids on vascular
function (i.e., vasoconstrictive effects, changes of smooth muscle cell and endothelial cell),
and the mechanisms currently thought to be involved.
Effects on Vascular Smooth Muscle
Vascular smooth muscle is the middle of the three concentric layers of blood
vessels, and is important in regulating the caliber of the blood vessels by contraction or
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relaxation (Strickland et al., 2009b). Endothelium lines the interior surface of blood
vessels and regulates vascular homeostasis by interacting with a variety of paracrine
factors (Vita and Keaney, 2002). Symptoms of fescue foot were first induced in calves
given ethanolic extracts of tall fescue hay (Williams et al., 1975). They also reported that
calves that had fescue foot had concomitant thickening of vessel walls and smaller vessel
lumens in blood vessels of the coronary bands and tail tips. Garner and Cornell (1978)
reported similar observations with a thickening of the smooth muscle layer of peripheral
blood vessels after consumption of endophyte-infected tall fescue. However, it was
unclear whether the growth of smooth muscle cells is based on a mechanism of
hyperplasia or hypertrophy. Later, the findings of Strickland et al. (1996) appear to favor
hyperplasia over hypertrophy as a possible mechanism. They reported that ergonovine,
ergovaline and α-ergocryptine stimulate the growth of quiescent bovine vascular smooth
muscle cells in vitro. However, inhibitory effects of bromocriptine (a semisynthetic
derivative of peptide alkaloids) on growing vascular smooth muscle cell proliferation was
observed in vitro in the rat and human (Zhang and Cincotta, 1997). Similarly, ergovaline
inhibited the growth of growing bovine vascular smooth muscle cells (Strickland et al.
(1996).
Effects on Vascular Endothelium
The endothelium is also highly suspected to be impacted by ergot alkaloids
(Strickland et al., 2009b). There was a debate based on whether ergot alkaloids have
direct influence on endothelial cells or not. One argument was that instead of toxic effects
of ergot alkaloids (ergotamine), blood vasoconstriction caused endothelial damage (Lewis
10

and Gelfand, 1935). These workers found that a necrosis was induced in the fowl’s comb
by ergotamine and further concluded that vasoconstriction alone did not necessarily
cause gangrene until the endothelial damage appears as a consequence of prolonged
vasoconstriction. Their point of view was supported by Thompson et al. (1950) who
reported a migrainous case subject with non-gangrenous arteriospam with no organic
changes in the small vessels. On the other hand, ergot alkaloids were reported to induce
bovine dorsal pedal vein endothelial cell death in cultures (Shappell, 2003). In
consideration of the concentration of ergot alkaloids used in this study was relatively
higher than natural grazing scenarios and further research is needed to support Shappell’s
argument.
Vasoconstrictive Effects
Regardless of the contradictory findings in vascular smooth muscle cell and
endothelial cell, ergot alkaloids have produced vasoconstrictive effects in a variety of in
vivo and in vitro research. Due to the intimate relationship of fescue toxicosis symptoms
(e.g., gangrene in extremities and elevated body temperatures) and peripheral
vasoconstriction, caudal artery (Aiken et al., 2007; Aiken et al., 2009), dorsal pedal vein
(Solomons et al., 1989) and lateral saphenous vein (Klotz et al., 2006) have been used by
several studies as a peripheral blood vessel model. Other models [e.g., right ruminal
artery and vein (Klotz et al., 2011), mesenteric artery and vein (Klotz, 2014)] have also
been developed in order to investigate the effects of ergot alkaloids on core blood vessels
and their interaction with nutrient absorption.
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However, there is only one published paper focusing on the effects of whole body
vasculature by ergot alkaloids in sheep and cattle (Rhodes et al., 1991). Using radiolabeled
microspheres, they reported that reduced (P < 0.10) blood flow occurred lower in hind
leg skin and adrenal glands by wethers fed a high alkaloid (1.18 ppm ergovaline) diet.
Similar blood flow reductions to the rib skin (P = 0.002), duodenum (P = 0.084), colon (P
= 0.080) and kidney (P = 0.118) were reported in cattle fed a high endophyte (0.52 ppm
ergovaline) diet under high ambient temperatures (32℃.) (Rhodes et al., 1991). These
findings might explain the higher rectal temperature of animals exposed to endophyteinfested tall fescue. The constricted blood vessel reduces its vessel caliber and therefore
limits the blood flow to peripheral tissues, which results in inefficiency of body heat
dissipation from core body to the surface (Strickland et al., 2009a).
Several other in vivo studies have been conducted to investigate the
vasoconstrictive effects of ergot alkaloids on peripheral blood vessel models. A modified
mercury-in-rubber strain gauge and plethysmographic from human limb model (Whitney,
1953) was used to measure the blood flow in the tail of dairy Heifers (Walls and Jacobson,
1970). They reported that heifers treated with an alcoholic extract of fescue hay (likely
contains ergot alkaloids) showed a decreased blood flow in the tail. Aiken and colleagues
conducted two experiments to investigate the hemodynamic responses of the caudal
artery by using color Doppler ultrasonography (Aiken et al., 2007; Aiken et al., 2009). They
found a decreased caudal artery area and blood flow after heifers exposed to endophyte
infested tall fescue.

12

An in vivo trial was designed to evaluate the impact of ergot alkaloids on
reticuloruminal epithelial blood flow at thermoneutral (22 ℃) and heat stress (32 ℃)
(Foote et al., 2013). The epithelial blood flow was measured as ruminal clearance of D2O
corrected for influx of physiological water and liquid outflow. They reported that ergot
alkaloids from an endophyte infected tall fescue seed extract (0.015 mg ergovaline · kg
BW-1·d-1) caused at least a 50% reduction in epithelial blood flow of steers regardless of
temperature. In addition, a reduced VFA absorption was observed and suspected to be
associated with the reduction in blood flow to the absorptive surface of the foregut (Foote
et al., 2013).
A series of bioassays have been developed to address the effects of ergot alkaloids
on blood vascular functions in livestock. This approach allows researchers to investigate
the effects of individual ergot alkaloid on certain target blood vessels, while in vivo trials
are extremely difficult to create these specific combinations (Strickland et al., 2009b).
Therefore, this methodology is not only suitable to studies looking at detailed dose
response of certain ergot alkaloids and blood vessel combinations, but also is able to
evaluate and compare the vasoconstrictive potency and efficacy of individual ergot
alkaloids. What’s more, the direct dose of ergot alkaloids to target blood vessels in vitro
will eliminate the possible interference that may be induced from the interactions of
ergot alkaloids with other physiological systems. As mentioned in the previous section,
the differences in ergot alkaloids on chemical structure and abundance in endophyte
infested tall fescue has raised the question of which single ergot alkaloid contributes more
to the vasoconstriction? In other words, the potency and efficacy have become the
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interest of many studies, in terms of understanding the pharmacological mechanism of
ergot alkaloid on vasculature.
An in vitro bioassay based on bovine dorsal pedal vein was developed by Solomons
et al. (1989) and reported that ergotamine, agroclavine and ergosine were able to elicit
constriction of bovine dorsal pedal vein. Ergotamine induced the highest maximal
contractile force, as well as required the lowest concentration to induce a constrictive
response. A series of studies, using a similar bioassay, have been conducted to investigate
the potency and efficacy of certain ergot alkaloids on bovine lateral saphenous vein
(model of peripheral vessels) (Klotz et al., 2006; 2007; 2008, 2010; Pesqueira et al., 2014).
Ergotamine and ergovaline produced similar contractile responses on saphenous veins in
terms of initial contractile responses (both at 1×10-8 M) and maximum contractile tension
(Klotz et al., 2007). However, lysergic acid was reported to induce an appreciable
contractile response at 1×10-4 M, and where maximum contractile force was achieved
(15.6 ± 2.3% of norepinephrine response) (Klotz et al., 2006). Based on these, it is
reasonable to say ergotamine and ergovaline are more toxic to bovine lateral saphenous
vein than lysergic acid, with at least 1000-fold more potency and 5-fold more efficacy
(Strickland et al., 2011).
Other ergot alkaloids, ergonovine, α-ergocryptine, ergocristine, and ergocornine
induced contractile responses on the saphenous vein, and potency and efficacy were
intermediate to ergovaline and lysergic acid (Klotz et al., 2010). The structural differences
among ergot alkaloids were thought to impact their affinity or mode of binding to
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serotonin receptors (Choudhary et al., 1995), which could result in different contractile
response and potency.
Other than peripheral vessel models (i.e., dorsal pedal vein, lateral saphenous
vein), this bioassay have been applied on core vessels such as the right ruminal artery and
vein (Foote et al., 2011; Klotz et al., 2011), and mesentery artery and vein (Egert et al.,
2014) to determine the effects of ergot alkaloids on vascular function and further
interactions with gut physiology. Derived from their previous peripheral lateral
saphenous vein model (Klotz et al., 2006), Klotz et al. (2011) developed and validated a
vascular contractility bioassay using bovine right ruminal artery and vein, to determine
the vasoconstrictive potentials of ergovaline, ergotamine, ergocryptine, ergocristine,
ergonovine, ergocornine and lysergic acid (Foote et al., 2011). They reported, in both
vessel types, lysergic acid failed to induce a contractile response, which was contradicted
to the findings that lysergic acid is vasoconstrictive on the lateral saphenous vein (Klotz
et al., 2006; Klotz et al., 2008). However, the appreciable contractile response was not
observed until lysergic acid at 10-4 M, which is not an achievable concentration for natural
grazing animals. Foote et al. (2011) also found ergotamine and ergovaline were potent
vasoconstrictors with relatively lower EC50 (indicator of potency) and higher Emax
(indicator of efficacy) than other ergot alkaloids in both ruminal arteries and veins, which
was in agreement with previous saphenous vein studies.
It may not be appropriate to compare ergot alkaloid’s potency and maximum
contractile force in an absolute magnitude between this (Foote et al., 2011) and previous
saphenous vein studies (Klotz et al., 2006; Klotz et al., 2007; Klotz et al., 2008, 2010), since
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there are differences in several vital setups between the two bioassays (e.g., Instead of
norepinephrine, 0.12 M KCl was used as a reference compound in ruminal artery and vein
model. (Klotz et al., 2011)). Nevertheless, taken together, these findings demonstrated
that both ergotamine and ergovaline are potent vasoconstrictors, while lysergic acid is
unable to cause vasoconstrictions of bovine tissues under normal physiological conditions.
Based on available data (Hill et al., 2001; Ayers et al., 2009), the small intestine
may be the major absorption site of ergopeptine alkaloids (Strickland et al., 2011). What’s
more, the mesenteric vein is one of the two outlets of transporting ergot alkaloids after
they cross the gastrointestinal epithelia, which leads to portal vein and liver (Eckert et al.,
1978). Thus, a bioassay was derived from the previous right ruminal artery and vein model
(Klotz et al., 2011) to profile the vasoactivity of ergot alkaloids in the bovine mesenteric
artery and vein (Egert et al., 2014). Similarly, ergocryptine, ergotamine, ergocristine,
ergocornine, ergonovine, and ergovaline-containing tall fescue seed extract, and
serotonin were all observed to induce a contractile response on mesenteric artery and
vein, with the exception of lysergic acid. They also reported that steers with previous
dietary exposure to endophyte-infested tall fescue seed had decreased or lacked a
constrictive response to many ergot alkaloids in the small intestine vasculature (Egert et
al., 2014), which were consistent with the findings in lateral saphenous vein (Klotz et al.,
2012; Klotz et al., 2013).
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Mechanisms
Given the studies above, ergot alkaloids associated with endophyte infested tall
fescue are able to induce vascular contraction in multiple tissues of different animal
models. Therefore, they have been attributed as the major causative agents of fescue
toxicosis. The core ergoline ring system of ergot alkaloids shares some structural
similarities with several biogenic amines (i.e., (nor)epinephrine, serotonin, and dopamine)
(Weber, 1980), which may confer to ergot alkaloids the ability to interact with
corresponding biogenic amine receptors (Berde, 1980). Several pharmacological
researchers have provided evidence of α-adrenergic receptors that are associated with
ergot alkaloids and blood vessel interactions (Byrne-Quinn, 1964; Fedotin and Hartman,
1970; Greene et al., 1977). Although the exact mechanisms behind them are not fully
defined, several in vitro vascular studies in livestock have reported that ergot alkaloids
induced vasoactivity is mediated via several biogenic amine receptors (Table 1.2).
One of the first reports of ergot alkaloids interacting with serotonergic receptors
was demonstrated by Dyer (1993). He reported that ergovaline induced contractions of
bovine uterine and umbilical arteries were blocked by ketanserin and phenoxybenzamine
(both 5HT2A antagonist) but not by prazosin or phentolamine (both α 1-adrenergic
antagonist), which indicated 5HT2A receptors but not α1-adrenergic receptors were
involved in the vasoconstriction. In contrast, Schoning et al. (2001) found that the
ergovaline induced rat thoracic aorta contractile response was via α 1-adrenergic
receptors. They also reported that ergovaline and ergotamine are equally effective as a
partial agonist in rat tail artery, and their vasoconstrictive responses were antagonized by
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ketanserin (5HT2A antagonist), which was in agreement with Dyer’s findings. What’s more,
these two studies both indicated that the binding of ergovaline and 5HT 2A serotonergic
receptor was irreversible, and the dissociation from the receptor was slow (Dyer, 1993;
Schoning et al., 2001). In the latter study, ergovaline also induced contractile responses
in guinea pig iliac artery via the 5HT1B/1D serotonergic receptor, and interestingly, it acted
as an agonist and (or) antagonist at the 5HT1B/1D receptor. However, Oliver et al. (1993)
demonstrated that lysergamide (ergine) was a partial agonist or antagonist at α 1adrenergic and α2-adrenergic receptors, respectively, in a bovine lateral saphenous vein
model. Likewise, lysergamide could induce contraction of saphenous vein via 5HT 2A
receptors but not 5HT1 receptors (Oliver et al., 1993). Using the same bovine lateral
saphenous vein model, Klotz et al. (2012) found DOI (5HT2A receptor agonist) induced
vessel contractile intensities were 35% lower (P < 0.05) in high endophyte-infested tall
fescue than in low endophyte-infested tall fescue, whereas 5CT (5HT7 receptor agonist)
produced greater (37%, P < 0.05) contractile intensities in high endophyte-infested tall
fescue. Therefore, they indicated that chronic exposure to ergot alkaloids through grazing
endophyte-infested tall fescue altered the vasoconstriction via serotonergic receptors,
but in different manners. In a subsequent study (Klotz et al., 2013) they reported
ketanserin (5HT2A receptor antagonist) reduced the contractile response to ergovaline,
ergotamine, and ergocornine, but SB-269970 (5HT7 receptor antagonist) was ineffective
at altering the contractile response.
In general (Table 2), there is evidence that ergot alkaloids interact with adrenergic
and serotonergic receptors as partial agonists or antagonists. The interaction between
18

specific receptor subtypes and ergot alkaloids varies among tissue types, as well as animal
models. Future studies are necessary to better understand the mechanism of ergot
alkaloid induced vasoconstriction at the receptor level, which is important to researchers
in terms of discovering therapeutic solutions for fescue toxicosis.
Isoflavones
Introduction
Phytoestrogens are broadly defined as a group of naturally occurring compounds
in plants that can exert estrogenic activities (Setchell, 1998). Usually these plant-derived
nonsteroidal molecules execute more “important” functions in animals than in plants,
where they mainly function as antioxidants (Anderson and Garner, 1997). The most
conspicuous character of the phytoestrogens is a diphenolic ring with structural
similarities of mammalian estrogens (Setchell and Adlercreutz, 1988). It is not surprising
that phytoestrogens bind to estrogen receptors and act as estrogen agonist or antagonist
(Shemesh et al., 1972; Verdeal et al., 1980; Barnes and Peterson, 1995; Makela et al.,
1995a; Makela et al., 1995b). This interaction with estrogen receptors offers the
possibility of phytoestrogens being potential alternatives therapies for several hormone
dependent conditions, such as cancer, menopausal symptoms, cardiovascular disease and
osteoporosis (Vitale et al., 2013). The abundant natural sources of phytoestrogens has
been discovered with the development of screening and identification technologies.
Although phytoestrogens are restrictedly distributed in the plant kingdom, more than 300
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plants have been identified so far to induce estrogenic responses in animals (Bradbury
and White, 1954; Farnsworth et al., 1975; Whitten and Patisaul, 2001).
There are three major classes of phytoestrogens, isoflavones, coumestans, and
lignans (Kurzer and Xu, 1997). These have always been the interest of studies from a
nutritional and health-promoting perspective. Isoflavones are the most commonly
studied form of phytoestrogens, and are almost exclusively found in the legume
(Leguminosae/Fabaceae) family (Franke et al., 1994; Reinli and Block, 1996). Soybeans
and soy products are the major source of dietary isoflavones, and contain genistein,
daidzein, and glycitein (Murphy, 1982; Coward et al., 1993; Wang and Murphy, 1994).
Many clinical studies in humans, animals, and cell culture systems have addressed these
two compounds in terms of investigating the potential health benefits of soy and soy
products. Other than the soybean, chick peas, red clover, toothed medic, and bluegrass
are all isoflavone containing sources (Price and Fenwick, 1985). Compared with soybeans,
red clover contains more varieties of isoflavones, such as genistein, daidzein, biochanin A
and formononetin (Beck et al., 2005). Structurally, biochanin A and formononetin are the
4’-methyl ethers of genistein and daidzein, respectively (Figure 4) (Kurzer and Xu, 1997).
Isoflavones and Impacts on Human and Animal Health
Long term hormone therapies on postmenopausal women have been reported to
induce some unexpected side-effects, such as increased risks of breast cancer
(Investigators, 2002; Beral et al., 2003; Anderson et al., 2004). Thus, finding an alternative
compound to substitute conventional steroid hormone would be desirable.
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Phytoestrogens, especially isoflavones, with weak estrogenic action, may be a potential
candidate. However, substantial evidence has been provided by a variety of clinical
human trials, animal and cell/tissue culture studies to indicate that isoflavones have
different beneficial effects on humans in many different ways, such as cardiovascular
system, osteoporosis, breast and prostate cancer (Anderson and Garner, 1997; Kurzer and
Xu, 1997; Dixon, 2004; Beck et al., 2005).
It is not the intent to review the physiological effects of isoflavones on these
different systems, neither to discuss the mechanisms associated with them. In this section,
the topic will be mainly focusing on the effects of isoflavones on vasculature and the
possible cellular or molecular mechanisms behind them.
Physiological Effects of Isoflavones on Vasculature
Substantial evidence has been reported on the vasodilative effects of isoflavones
and their metabolites in different vessel types in humans (Walker et al., 2001; ChinDusting et al., 2004) and rats (Gimenez et al., 1997; Chin-Dusting et al., 2001; Jackman et
al., 2007; Wu et al., 2010). Some of the first information about isoflavone metabolite
activities in blood vessels was reported by (Gimenez et al., 1997). They indicated that
equol induced a modest vasorelaxation with was 10-fold more potent than furosemide
on precontracted isolated rat aortic rings. As many metabolic studies have found, daidzein
is metabolized by intestinal bacteria to equol, which has a higher estrogenic potency than
pure isoflavones (Dixon, 2004; Beck et al., 2005). Equol was also detected in plasma and
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urine of sheep after intraruminal infusion of formononetin (Braden et al., 1967), as well
as in sheep grazing clover (Shutt and Braden, 1968).
Chin-Dusting et al. (2001), using rat isolated aortic rings, reported 17β-oestradiol,
equol, and four other isoflavone metabolites, dihydrodaidzein, cis-tetrahydrodaidzein,
trans-tetrahydrodaidzein, and dehydroequol all significantly antagonized contractile
responses to noradrenaline. What’s more, dose-dependent vasodilatory responses were
observed in noradrenaline precontracted rat aorta by 17β-oestradiol and five other
isoflavone metabolites (Chin-Dusting et al., 2001).
Equol also showed vasorelaxant activity in rat carotid arteries in vitro and rat
basilar arteries in vivo as a potent compound similar with daidzein (Jackman et al., 2007).
This finding was consistent with the vasorelaxant effect of daidzein found in rabbit basilar
(Torregrosa et al., 2003) and rat mesenteric arteries (Nevala et al., 1998). Other
isoflavones, formononetin and biochanin A were also reported to relax contracted rat
aortic rings induced by phenylephrine in a dose-dependent manner (Wu et al., 2010).
An in vivo study by Chin-Dusting et al. (2004) was the first report of a direct
dilatory effect of an isoflavone metabolite in humans. They demonstrated that
dehydroequol caused a significant vascular dilation in the forearm resistance arteries.
Likewise, brachial artery administration of the isoflavone genistein was reported to
increase the blood flow of forearm resistance artery, which was interpreted as an
outcome of vasodilation (Walker et al., 2001). However, the exact mechanisms of
isoflavone and their metabolites as vasodilators have not been fully elucidated.
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Substantial human, animal, and cell/tissue culture studies have indicated that
isoflavones and their metabolites induced vasodilation was mediated by endothelium.
The endothelium of the vascular system plays important roles on regulating blood flow,
vascular tone, vascular smooth muscle growth, inflammation, coagulation and fibrinolysis
(Hall et al., 2005). The release of nitric oxide (NO) mainly triggers the endotheliumdependent vasodilation, which relaxes the smooth muscle and dilates the vessel. In
endothelium, NO is produced by endothelial NO synthase (eNOS) (Hall et al., 2005). In
vitro evidence was provided by several animal trials, which found genistein, daidzein and
isoflavone metabolites induced vasodilative response was endothelium dependent on rat
aortic rings (Chin-Dusting et al., 2001), pulmonary arteries (Karamsetty et al., 2001), and
abdominal aorta (Jiang et al., 2003). In vivo studies reported that brachial artery
administration of genistein caused vasodilation which was antagonized by eNOS inhibitor
L-NMMA (Walker et al., 2001). What’s more, both elevated vasodilation and eNOS activity
were reported in ovariectomised rats consuming dietary isoflavones (Yamaguchi et al.,
2001; Catania et al., 2002). Genomic and non-genomic endoplasmic reticulum-mediated
activation of eNOS were believed to be responsible for the stimulation of NO production
by isoflavones (Hall et al., 2005).
In contrast, genistein and daidzein were reported to cause vasodilative responses
even when endothelium was denuded in rat aortic arteries (Li et al., 2004), and rat
mesenteric arteries (Nevala et al., 1998). In addition, Jackman et al. (2007) demonstrated
that the vasorelaxation of carotid arteries in vitro and basilar artery in vivo to equol was
independent of endothelium and eNOS activity. At present, there is no exact answer as
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to whether the vasodilative response to isoflavone and its metabolites is wholly
endothelium dependent or independent, and the mechanism of isolated isoflavones
varies among different tissue types of different animal models.
Interestingly, an in vitro study indicated that genistein-induced vascular relaxation
of rabbit femoral arteries was partially endothelium-dependent, and a calcium
antagonistic mechanism was involved after the removal of endothelium (Ji et al., 2002).
Similarly, Wu et al. (2010) suggested that formononetin caused vasorelaxation in rat
aortic arteries via both endothelium dependent and independent pathways. They
reported that the activation of large conductance Ca2+-dependent K+ (BKCa) channels and
ATP-sensitive K+ channel (KATP) was involved in endothelium independent mechanism.
Again, more evidences are necessary to better understand the molecular mechanisms of
isoflavones as a vasodilator.
Conclusion
Interaction of Ergot Alkaloids and Isoflavones
Implantation of steroid hormones have been shown to increase body weight gain of
calves grazing endophyte-infested tall fescue (Davenport et al., 1993; Bransby et al., 1994;
Coffey et al., 2001; Aiken et al., 2006). What’s more, growth performance studies have
reported that addition of clover to infected tall fescue increased steer gain significantly
(Thompson et al., 1993). The dilution of toxic tall fescue by clover was thought the reason
for the positive impacts on performance. As mentioned in the last chapter, red clover
contains a variety of isoflavones, such as genistein, daidzein, biochanin A and
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formononetin (Beck et al., 2005). It is possible that the isoflavone and ergot alkaloid
interaction was part of the reason to cause impact in performance mentioned above.
However, more information about the interaction of ergot alkaloids and isoflavones are
necessary, especially in terms of its potentially positive effects on fescue toxicosis.
Objectives
Substantial evidence has shown that ergot alkaloids and isoflavones are able to elicit
opposing physiological activities on the vasculature. Ergot alkaloids share some
structurally similarities with biogenic amines (i.e. dopamine, epinephrine, norepinephrine,
serotonin) and thus can induce vasoconstriction by binding biogenic amine receptors. On
the other hand, isoflavones have estrogenic activities and might be able to cause
endothelium dependent or independent vasorelaxation. Although the exact mechanisms
of their vascular bioactivities have not been fully defined, current knowledge indicates
that these vascular reactions are triggered by different mechanisms. Nevala et al. (1998)
reported that isoflavones relax noradrenaline pre-contracted rat mesenteric arteries.
Likewise, Egert et al. (2014) demonstrated that ergot alkaloids were vasoactive in bovine
mesenteric vasculature, as well as dietary exposure to ergot alkaloids decreased the
contractility of mesenteric vasculature. Thus, it is hypothesized that isoflavones may
attenuate ergot alkaloid induced vasoconstriction and further alleviate the diminished
contractility of mesenteric vasculature after pre-exposure to ergot alkaloids. The
objective of this study is to investigate the interaction of isoflavones and ergot alkaloids
on vasoactivity of bovine mesenteric vasculature and to determine if pre-incubation with
formononetin, biochanin A, or ergovaline-containing tall fescue seed extract and their
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combinations affect the ergotamine-induced contractility of bovine mesentery
vasculature.
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Table 1.1 Substituents of ergopeptide (Hafner et al., 2008).
Toxin
Ergocomine
Ergocristine
Ergotamine
Ergosine
α-Ergocryptine

Toxin group
Ergopeptide
Ergopeptide
Ergopeptide
Ergopeptide
Ergopeptide

Substituent R1
CH(CH3)2
CH2C6H5
CH2C6H5
CH(CH3)C2H5
CH(CH3)2

Substituent R2
CH(CH3)2
CH(CH3)2
CH3
CH3
CH3CHCH2CH3

27

Table 1.2 Ergot alkaloids and their biogenic amine receptors.

Ergot Alkaloid

Animal

Vessel type

Adrenergic receptor class

Serotonergic receptor class

Citation

Cow

Uterine and
umbilical
artery

Not by α1-adrenergic receptor

5HT2A

Dyer (1993)

Tail artery

ND

5HT2A

Thoracic artery

α1-adrenergic receptor

ND

Guinea
pig

Iliac artery

ND

5HT1B/1D

Ergotamine

Rat

Tail artery

ND

5HT2A

Ergine
(Lysergamide)

Lateral
saphenous
vein

α1-adrenergic receptor

5HT2A

Cattle

Ergovaline

Rat

Schoning et al.
(2001)
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Endophyteinfested tall
fescue

Cattle

Lateral
saphenous
vein

Oliver et al. (1993)
α2-adrenergic receptor

Not 5HT1

α2-adrenergic receptor

ND

ND

5HT2A
5HT7
5HT2A

Oliver et al. (1998)
Klotz et al. (2012)
Klotz et al. (2013)

Figure 1.1 Ergoline ring system.(Garner et al., 1993)
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Figure 1.2 Chemical structures of the common clavine alkaloids, lysergic acid derivatives, and ergopeptine alkaloids.
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Figure 1.3 General structure of ergopeptine alkaloids. (Hafner et al., 2008)
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Figure 1.4 Chemical structures of the isoflavones found in legumes. (Kurzer and Xu, 1997)
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Chapter 2. Materials and Methods
No live animals were involved this study, so approval from the University of
Kentucky Animal Care and Use Committee was not required.
Animals and Tissue Collection
Five Angus heifers (BW = 639 ± 39 kg) were slaughtered and tissues were collected
at the University of Kentucky abattoir. After the gastrointestinal tract was removed from
the carcass, the cecum, ileocecal fold, and the ileal flange were identified as landmarks.
Within the mesentery supporting the ileal flange, multiple branches of the mesenteric
artery and vein bundles were dissected out and submerged in oxygenated KrebsHenseleit buffer (95% O2/5% CO2; pH= 7.4; 11.1 mM D-glucose; 1.2 mM MgSO4; 1.2 mM
KH2PO4; 4.7 mM KCl; 118.1 mM NaCl; 3.4 mM CaCl2; 24.9 mM NaHCO3; Sigma Chemical
Co., St. Louis, MO) for transport to the laboratory. Samples were placed on ice until
cleaned. At the time of cleaning, surrounding fat and connective tissues were carefully
dissected away, and mesentery artery and vein were separated under a magnifying lamp
(2.5 to 5.0X magnification). Cleaned vessels were sliced into 2-mm segments and
examined under a dissecting scope (Semi 2000-C, Carl Zeiss Inc., Oberkochen, Germany)
at 12.5X magnification to ensure the usability of the vessels. Cross-sections with
abnormalities (branches, valves, or structural damage) were replaced with structurally
integral ones.
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Pre-myograph Incubations
A tall fescue seed extract was prepared as described by Foote et al. (2012) to
contain a 1 × 10-6 M working concentration of ergovaline. Duplicates of each vessel type
were incubated in tissue culture flasks with a 50-mL volume of Krebs-Henseleit buffer
containing: only buffer (Control); 1 × 10-6 M ergovaline-containing tall fescue seed extract
(EXT); 1 × 10-6 M formononetin (F; ≥ 99.0%; 47752-5MG-F; Sigma Chemical Co., St. Louis,
MO); or 1 × 10-6 M biochanin A (B; D2016; Sigma Chemical Co., St. Louis, MO); and
combinations of 1 × 10-6 M EXT and 1 × 10-6 M F (EXT + F); 1 × 10-6 M EXT and 1 × 10-6 M
B (EXT + B); 1 × 10-6 M F and 1 × 10-6 M B (F + B); or 1 × 10-6 M EXT and 1 × 10-6 M F and 1
× 10-6 M B (EXT + F + B). All buffer solutions were pre-warmed for 30 min in a CO2
incubator (95% O2/5% CO2; 37 ℃; Nu-8500, NUAIRE, Inc. Plymouth, MN) prior to blood
vessel addition. Duplicate blood vessel segments were randomly placed into each
treatment flask and incubated in the same conditions for 2 h. Immediately after the 2-h
incubation, dimensional measurements of cross-sections were recorded only for
mesentery artery using Axiovision (version 20, Carl Zeiss, Inc.).
Experimental Myograph Protocol
Following the incubations, an ergotamine concentration response experiment was
conducted using the procedures described by Egert et al. (2014) and Klotz (2014).
Ergotamine (ergotamine D-tartrate; 97%; 45510; Aldrich, Milwaukee, WI) standards were
prepared by diluting stock solutions (0.0201 M) with dimethyl sulfoxide to working
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concentrations that resulted in a concentration range of 5 × 10-9 to 1 × 10-4 M in the
myograph chamber (contained 5 mL of Krebs-Henseleit buffer).
Blood vessel cross-sections were gently mounted on the myograph (Multichamber
myograph; DMT 610M, Danish Myo Technology, Atlanta, GA) by inserting the supports
through the lumen in individual myograph chambers containing 5 mL modified KrebsHenseleit buffer and continuously gassing (95% O2/5% CO2; pH = 7.4; 37℃). The
incubation buffer was modified from transport Krebs-Henseleit buffer by adding
desipramine (3 × 10-5 M; D3900; Sigma Chemical Co.) to inhibit the reuptake mechanisms
of biogenic amines and propranolol (1 × 10-6 M; P0844; Sigma Chemical Co.) to block the
non-specific binding to β-adrenergic receptors. A 90-min equilibration period with buffer
replacement occurring every 15 min was completed based on the conditions above to
achieve a stable resting tension of approximately 1 g. After the completion of
equilibration, 500 μL of a 1.32 M KCl (Sigma Chemical Co.) solution, resulting in a 120 mM
KCl in a myograph chamber, was added and incubated for 15 min to evaluate tissue
viability and to be used to normalize treatment data. Incubation buffer was replaced
every 15 min until vessel tension returned to the 1 g baseline. Once the vessel returned
to baseline, addition of ergotamine standards were initiated in order of increasing
concentration. Ergotamine additions were added in 15-min intervals consisting of a 9-min
incubation period, two 2.5-min buffer washes, and a third, final buffer replacement that
was followed by 1-min recovery before the next ergotamine addition. This 15 min cycle
was repeated for the rest of the 9 remaining ergotamine additions. Following the 1-min
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recovery after the final ergotamine addition, vessels were again exposed to 120 mM KCl
to confirm the vessel viability at the end of the experiment.
Data Collection and Statistical Analysis
The isometric contractions of the different pre-incubated mesenteric vessels to
KCl and ergotamine additions were digitized and recorded as grams of tension using a
PowerLab/8sp and Chart software (version 7.3, ADInstruments, Colorado Springs, Co.).
Baseline tension was measured immediately before the addition of 1.32 M KCl. For all
contractile response data, the maximum observed tension (g) in the 9 min-incubation
period was recorded as the contractile response. Contractile response data were
corrected for baseline tension (subtraction of the baseline measurement) and normalized
as a percentage of the reference compound KCl induced maximum contractile response
(grams of tension). The differences of tissue response due to the variations of vessel size
and individual animal were taken into account by this data normalization. The contractile
response to ergotamine was determined and presented as percentage means ± SEM. A
measurement of potency, or the half maximal effective concentration (EC50) was
calculated by GraphPad Prism software 5 (GraphPad Software Inc., La Jolla, CA) using a
nonlinear regression with fixed slope. The sigmoidal concentration response curves of
pre-treated mesentery artery and vein to ergotamine was plotted by using a 3-parameter
equation:
(top−bottom)

𝑦 = bottom + [1+10(𝑙𝑜𝑔𝐸𝐶50−𝑥)] ,
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where top and bottom are the plateaus of contractile response as percentage of 120 mM
KCl maximum response. EC50 is the molar concentration of ergotamine inducing 50% of
the KCl maximum response.
All data were analyzed using the MIXED model of SAS (SAS 9.4, SAS Inst. Inc., Cary,
NC). Contractile response data of mesentery artery and vein were analyzed separately as
two groups: treatments with and without EXT. Data for contractile response (within each
ergotamine concentration), KCl maximal response, inside and outside diameters for
mesenteric artery (data could not be obtained for mesenteric vein samples) were
analyzed as a completely randomized design with a factorial treatment arrangement. The
fixed effects included the effects of F, B, and the interaction of F × B in the presence or
absence of EXT. Due to the shape of the response curve, EC50 data were analyzed only in
treatments without EXT from mesentery artery using a completely randomized design
with treatment as fixed variable. For all data, an ANOVA was conducted and pair-wise
comparisons of least square means (± SEM) were performed if the probability of a greater
F-statistic was significant for the tested effect and interaction. Mean separation was
performed with the LSD feature of SAS. Differences are denoted as significant at P < 0.05,
unless specifically reported otherwise.
Chapter 3. Results
The F and B incubation pre-treatment did not impact (P > 0.05) the maximum
contractile response of mesenteric artery or mesenteric vein to 120 mM KCl either
without EXT (Table 3.1) or with EXT (Table 3.2). The pre-treatments with EXT did not
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compromise the vessel viability, which was indicated by the ending response to KCl for
either the artery or vein (Figure 3.1). In mesenteric artery, the inside and outside diameter
after the 2 h incubation were not affected (P > 0.05) by F or B in both treatments groups
with or without EXT (Table 3.1, Table 3.2). However, these was a tendency (P < 0.1) for F
treated vessels to have a larger inside diameter for those pretreated with EXT, and a
smaller outside diameter for those pretreated without EXT (Table 3.2).
In the mesenteric artery, ergotamine induced similar contractile responses in all
treatments (Figure 3.2a) with -logEC50 values (5.99 ± 0.14 M, 5.80 ± 0.14 M, 5.88 ± 0.14
M, 5.74 ± 0.14 M, respectively) that did not differ with each other (P = 0.6338). Within
each ergotamine concentration, tendencies for F × B interactions in mesenteric artery
were observed at ergotamine 5 × 10-9 M, 1 × 10-8 M, 5 × 10-8 M (P = 0.0932, P = 0.0703, P
= 0.0840, respectively; Table 3.3) for treatments without EXT. Contractile responses of F
+ B treated mesentery artery were greater than B at ergotamine concentrations 1 × 10-8
M and 5 × 10-8 M (P < 0.05). In mesenteric vein, ergotamine induced contractile responses
reached the maximum response at 1 × 10-6 M for Control, B, F, F + B treatments (Figure
3.2b), and then declined to negative values with increases in ergotamine concentration.
For the blood vessels incubated with EXT the contractile responses decreased as
the concentration of ergotamine increased in both mesenteric artery and mesenteric vein
(Figure 3.2c, 3.2d). In mesenteric artery, a main effect of B was observed at ergotamine
concentrations of 1 × 10-7 M and 5 × 10-7 M (Table 3.4), with treatments that contained B
having higher contractile responses (P < 0.05). Also, treatments containing B tended (P <
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0.1) to have greater responses than treatments without B at ergotamine concentrations
of 1 × 10-6 M, 5 × 10-6 M, and 5 × 10-5 M (Table 3.4).
In the mesenteric vein, the contractile response of all treatments with EXT to
ergotamine decreased and remained below zero from the second ergotamine addition (1
× 10-8 M) to the last addition at 1 × 10-4 M. Tendencies for main effects of B (P = 0.06) and
a F × B interaction (P = 0.09) were observed at ergotamine concentrations of 5 × 10-9 M,
where EXT treatment had a lower contractile response than EXT + B (P < 0.05; Table 3.4).
Treatments containing F had greater contractile responses to ergotamine at 1 × 10-5 M, 5
× 10-5 M, and 1 × 10-4 M in mesenteric vein (main effect of F; P < 0.05; Table 3.4). Within
ergotamine concentrations, at 5 × 10-5 M the contractile response of EXT was the lowest
(P < 0.05).
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Table 3.1 Inside diameter, outside diameter and SEM of mesenteric artery, and the mean KCL maximum response of mesenteric artery and vein
to pre-treatment without tall fescue extract: only Krebs-Henseleit buffer (Control); 1 × 10-6 M formononetin (F); or 1 × 10-6 M biochanin A (B);
and combination of 1 × 10-6 M F and 1 × 10-6 M B (F + B)

Item

Control

F

B

F+B

SEM

KCL maximum response, g

4.36

4.42

4.22

3.66

Inside diameter, mm

0.81

0.79

0.86

Outside diameter, mm

1.72

1.64

1.70

1.81

P-value1
F

B

FxB

0.46

0.5837

0.3319

0.4951

0.77

0.06

0.3774

0.7714

0.6142

1.75

1.57

0.07

0.0901

0.7440

0.4721

1.89

2.22

0.21

0.3115

0.1784

0.6160

Mesenteric artery
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Mesenteric vein

KCL maximum response, g

1

F, main effect of formononetin; B, main effect of biochanin A; F x B, interaction of formononetin and biochanin A.

Table 3.2 Inside diameter, outside diameter and SEM of mesenteric artery, and the mean KCL maximum response of mesenteric artery and vein
to pre-treatment with tall fescue seed extract: 1 × 10-6 M ergovaline-containing tall fescue seed extract (EXT); combinations of 1 × 10-6 M EXT
and 1 × 10-6 M F (EXT + F); 1 × 10-6 M EXT and 1 × 10-6 M B (EXT + B); or 1 × 10-6 M EXT and 1 × 10-6 M F and 1 × 10-6 M B (EXT + F + B).

Item

EXT

EXT + F

EXT + B

EXT + F + B

SEM

KCL maximum response, g

3.43

2.68

3.08

2.84

Inside diameter, mm

0.72

0.78

0.60

Outside diameter, mm

1.64

1.57

1.90

2.20

P-value1
F

B

FxB

0.37

0.1887

0.8022

0.5010

0.72

0.05

0.0742

0.0649

0.5034

1.51

1.59

0.07

0.9189

0.4256

0.2855

2.09

2.49

0.21

0.1110

0.2646

0.8146

Mesenteric artery
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Mesenteric vein

KCL maximum response, g

1

F, main effect of formononetin; B, main effect of biochanin A; F x B, interaction of formononetin and biochanin A.

Table 3.3 The analysis of variance and P-values of main effect of formononetin (F), biochanin A (B), and the interaction of formononetin and
biochanin A (F x B) for pre-treatments without tall fescue extract: only Krebs-Henseleit buffer; 1 × 10-6 M formononetin; or 1 × 10-6 M biochanin
A; and combination of 1 × 10-6 M formononetin and 1 × 10-6 M biochanin A on every ergotamine concentration.
Ergotamine
Concentration, M
Mesenteric artery
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5x10-9
1x10-8
5x10-8
1x10-7
5x10-7
1x10-6
5x10-6
1x10-5
5x10-5
1x10-4

F

P-value1
B

FxB

0.2281
0.1446
0.1963
0.2943
0.8788
0.6784
0.2674
0.3790
0.4322
0.6140

0.9117
0.2723
0.5085
0.8303
0.7897
0.7843
0.9888
0.9720
0.8098
0.5352

0.0932
0.0703
0.0840
0.3059
0.4319
0.6378
0.7172
0.9700
0.7747
0.5949

0.9175
0.9963
0.6737
0.7952
0.9871
0.9304
0.7795
0.5048
0.2860
0.2286

0.2667
0.9648
0.6700
0.6422
0.4340
0.2983
0.4265
0.7964
0.9309
0.8638

0.8545
0.5015
0.2827
0.4082
0.7427
0.7009
0.6996
0.6229
0.6051
0.8886

Mesenteric vein
5x10-9
1x10-8
5x10-8
1x10-7
5x10-7
1x10-6
5x10-6
1x10-5
5x10-5
1x10-4
1

F, main effect of formononetin; B, main effect of biochanin A; F x B, interaction of formononetin and biochanin A.

Table 3.4 The analysis of variance and P-values of main effect of formononetin (F), biochanin A (B), and the interaction of formononetin and
biochanin A (F x B) for pre-treatments with tall fescue seed extract: 1 × 10-6 M ergovaline-containing tall fescue seed extract; combinations of 1 ×
10-6 M ergovaline-containing tall fescue seed extract and 1 × 10-6 M formononetin; 1 × 10-6 M ergovaline-containing tall fescue seed extract and 1
× 10-6 M biochanin A; or 1 × 10-6 M ergovaline-containing tall fescue seed extract and 1 × 10-6 M formononetin and 1 × 10-6 M biochanin A on
every ergotamine concentration.
Ergotamine
Concentration, M
Mesenteric artery
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5x10-9
1x10-8
5x10-8
1x10-7
5x10-7
1x10-6
5x10-6
1x10-5
5x10-5
1x10-4

F

P-value1
B

FxB

0.9418
0.4289
0.2200
0.2009
0.2482
0.2109
0.2131
0.3070
0.2432
0.1788

0.7127
0.3081
0.1114
0.0438
0.0302
0.0572
0.0863
0.1269
0.0975
0.1170

0.6984
0.9555
0.7707
0.7342
0.5680
0.5798
0.5240
0.6992
0.8691
0.7737

0.7453
0.9145
0.4529
0.1753
0.1483
0.1872
0.1566
0.0339
0.0212
0.0059

0.0694
0.7666
0.9824
0.8547
0.4810
0.5756
0.4390
0.3013
0.1711
0.2382

0.0976
0.4060
0.5007
0.3217
0.1878
0.3217
0.2674
0.1160
0.0794
0.1359

Mesenteric vein
5x10-9
1x10-8
5x10-8
1x10-7
5x10-7
1x10-6
5x10-6
1x10-5
5x10-5
1x10-4
1

F, main effect of formononetin; B, main effect of biochanin A; F x B, interaction of formononetin and biochanin A.

Tension, g

(b)
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(a)

Tension, g

Figure 3.1 Example of a typical response of mesenteric artery (a) and vein (b) cross sections, after pre-treated with 1 × 10-6 M EXT and 1 × 10-6 M
F and 1 × 10-6 M B (EXT + F + B), to increasing concentrations of ergotamine (5 × 10-9 to 1 × 10-4 M). The rectangles highlighted region are the
initial and end KCl (0.12 M) additions.

Figure 3.2 Mean contractile response, as % KCl maximum of mesenteric artery (a, c) and vein (b, d) to increasing concentrations of ergotamine for
two groups of pre-treatments, without tall fescue seed extract: only Krebs-Henseleit buffer (Control); 1 × 10-6 M formononetin (F); or 1 × 10-6 M
biochanin A (B); and combination of 1 × 10-6 M F and 1 × 10-6 M B (F + B) (a, b); with tall fescue seed extract: 1 × 10-6 M ergovaline-containing tall
fescue seed extract (EXT); combinations of 1 × 10-6 M EXT and 1 × 10-6 M F (EXT + F); 1 × 10-6 M EXT and 1 × 10-6 M B (EXT + B); or 1 × 10-6 M EXT
and 1 × 10-6 M F and 1 × 10-6 M B (EXT + F + B) (c, d). The regression lines were plotted of each treatment using a nonlinear regression with fixed
slope and the sigmoidal concentration response curves were calculated by the following equation: y = bottom + [(top-bottom)/(1 + 10(𝑙𝑜𝑔𝐸𝐶50−𝑥 ) )],
where top and bottom are the plateaus of contractile response as percentage of 120 mM KCl maximum response. EC50 is the molar concentration
of ergotamine inducing 50% of the KCl maximum response.
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(a)

(b)

(c)

(d)

Chapter 4. Discussion and Conclusion
To our knowledge, this study was the first to investigate the interaction of
ergoalkaloids and isoflavones on in vitro mesenteric vasculature. Physiological effects of
isoflavones and their metabolites on vasculature have been extensively studied on
different vessel types in humans (Walker et al., 2001; Chin-Dusting et al., 2004), and rat
models (Gimenez et al., 1997; Chin-Dusting et al., 2001; Jackman et al., 2007; Wu et al.,
2010). However, to date, isoflavones’ vasoactivity have not been studied in bovine
mesenteric vasculature.
Several studies have demonstrated that cattle grazing endophyte-infected tall
fescue had reduced contractile responses to 5HT and as well as ergot alkaloids in the
lateral saphenous vein (Klotz et al., 2012; Klotz et al., 2013). Recently, a study using
mesenteric artery and vein from steers that had been intraruminally dosed with
endophyte-infected tall fescue seed observed a decreased or absent constrictive
response to ergot alkaloids (Egert et al., 2014). In the current study, an in vitro premyograph incubation of bovine mesenteric vasculature in the medium containing
endophyte-infected tall fescue seed extract was used to achieve an ergot alkaloid pretreatment. The endophyte-infected tall fescue seed extract (Foote et al., 2012) and
isoflavones (formononetin and biochanin A) were added to the myograph medium at
equimolar final concentrations of 1 × 10-6 M. It has been reported that formononetin and
biochanin A both induced vasorelaxation in phenylephrine precontracted rat isolated
thoracic aorta at 1 × 10-6 M (Wu et al., 2010). However, the 1 × 10-6 M ergovaline in the
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endophyte-infected tall fescue seed extract may be considered a high dose compared to
the physiological level encountered by cattle grazing endophyte-infected tall fescue.
Nevertheless, the viability of mesenteric artery and vein were not compromised by these
amounts of ergot alkaloids which was supported by the fact that they were both active to
the ending KCl addition.
Studies have reported that many isoflavones and their metabolites can reduce the
vasoconstriction induced by KCl in several different vessel types using rat models (Jiang
et al., 1991; Jackman et al., 2007). The contractile response to KCl of endothelium
denuded rat aortic rings was inhibited by pretreatment with genistein or daidzein at both
30 and 100 μM for 30 min (Seok et al., 2008). However, in the same study, pretreatment
with genistein or daidzein at 10 μM did not induce the vasorelaxation caused by KCl. The
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similar dose-dependent inhibition of formononetin (10, 30, and 100 μM) on the
contractile response to KCl was observed in rat mesenteric arteries without endothelium
(Sun et al., 2011), where formononetin again failed to inhibit KCl-initiated contraction at
10 μM. However, in endothelium-intact rat aortic rings, Zhao et al. (2012) reported that
pretreatment with 10, 30, and 50 μM of formononetin all significantly inhibited the
contractile response to KCl in a noncompetitive manner. In the current study, the prior
exposure to formononetin (1 μM), biochanin A (1 μM), and their combination did not have
an impact on maximum contractile response of mesenteric artery and vein to KCl in
treatments either with or without EXT. Since previous studies have indicated that the
inhibition effects were dose-dependent (Seok et al., 2008; Sun et al., 2011) and
noncompetitive (Zhao et al., 2012), it is possible the isoflavone concentration (1 μM) in
47

the current study was not high enough to elicit any inhibitory effects. However, in the
current study, from a perspective of reference compounds to normalize the contractile
responses, the unaffected maximum KCl response by formononetin and biochanin A were
critical.
There is limited information about isoflavones’ impact on blood vessel
morphology in regards to vessel inside and outside diameters. In the current study, there
was no evidence of a formononetin or biochanin A effect on mesenteric artery inside or
outside diameter regardless of EXT treatment. However, a tendency of smaller inside
diameter induced by formononetin treatment was observed in mesentery artery pretreated without EXT. One possible explanation for this could be the inhibitory effect of
formononetin on vascular smooth muscle cells. Previously, estrogens (tamoxifen
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(Grainger and Metcalfe, 1996), estradiol (Rosselli et al., 1994)) and phytoestrogens
(formononetin and biochanin A (Dubey et al., 1999) have been shown to inhibit mitogeninduced proliferation, migration and extracellular matrix synthesis of smooth muscle cells.
On the other hand, the inside diameter of bovine lateral saphenous veins collected from
steers grazing high-endophyte tall fescue pasture were smaller than those from steers
grazing low-endophyte mixed-grass pasture (Klotz et al., 2012). Likewise, Egert et al.
(2014) observed a smaller outside diameter of bovine mesenteric artery from endophyteinfected tall fescue seed dosed steers than control steers. One possible explanation is the
prolonged vasoconstriction induced by ergot alkaloids result in decreased inside or
outside diameter. Additionally, the morphological changes of blood vessels, especially the
expansion of the smooth muscle layer (tunica media), could also lead to a smaller vessel
48

insider diameter. It has been observed that calves given ethanolic extracts of tall fescue
hay had symptoms of fescue foot and concomitant thickening of vessel walls and smaller
vessel lumens in blood vessels of the coronary bands and tail tips (Williams et al., 1975).
Similarly, Garner and Cornell (1978) reported a thickening of the smooth muscle layer of
peripheral blood vessels after consumption of endophyte-infected tall fescue. Although
the exact mechanism associated with thickening of smooth muscle layer is unclear,
evidence suggests hyperplasia over hypertrophy. Strickland et al. (1996) reported that
ergonovine, ergovaline and α-ergocryptine stimulate the growth and mitosis of quiescent
bovine vascular smooth muscle cells in vitro. Although, in this study, there was no
significant impact of formononetin and biochanin A pre-treatment on mesenteric artery
inside or outside diameters, tendencies of larger inside diameter caused by formononetin
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and smaller inside diameter in biochanin A treated mesenteric artery were observed. This
controversial observation could not be well explained based on our current knowledge.
However, besides vasoconstriction and vasodilation, many other factors could influence
the inside or outside diameter, such as vascular smooth muscle hyperplasia and
hypertrophy.
In the current study, the ergotamine induced similar contractile response curves
in mesenteric artery, and with –logEC50 values that did not differ among treatments
without EXT. The shape of contractile responses were similar with Egert et al. (2014), who
reported ergotamine induced contractile responses in mesenteric artery from steers, not
exposed to ergot alkaloids, with a –logEC50 value of 6.03 ± 0.4 M. Whereas, in mesenteric
vein, the shape of contractile response curves were in contrast to the observations of
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Egert et al. (2014), which did not drop to negative values after peak. Further, the
maximum contractile response of mesenteric vein to ergotamine in the current study was
also lower (10% vs. 45% of KCl maximum). It has to be mentioned that the blood vessels
used in the previous study (Egert et al., 2014) did not undergo pre-myograph incubation.
So, taken together, the 2-hr pre-myograph incubation in the current study seemed to alter
the contractile response of mesenteric veins in terms of potency and efficacy to
ergotamine.
Substantial evidence has shown many ergot alkaloids are vasoconstrictive in
multiple tissues of different animal models (Strickland et al., 2009b; Strickland et al.,
2011). Among these vasoactive ergot alkaloids, ergotamine and ergovaline were indicated
as more potent vasoconstrictors with relatively lower EC50 values in bovine saphenous
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vein (Klotz et al., 2007), ruminal vasculature (Foote et al., 2011), and mesenteric
vasculature (Egert et al., 2014). The current observation of the contractile response
induced by ergotamine was consistent with these previous findings. Even though not
completely defined yet, numerous studies have been conducted to investigate the
mechanism of ergot alkaloid-caused vasoconstriction. The structural similarities of the
ergoline ring system and several biogenic amines (i.e., (nor)epinephrine, serotonin, and
dopamine) allows ergot alkaloids to interact with corresponding biogenic amine receptors
as ligands (Berde, 1980; Weber, 1980). Substantial evidences have shown that ergot
alkaloids interact with dopamine-2 receptor (Larson et al., 1994; Larson et al., 1995), α1adrenergic receptor (Oliver et al., 1993; Schoning et al., 2001), α2-adrenergic receptor
(Oliver et al., 1998), 5HT2A receptor (Dyer, 1993; Klotz et al., 2012; Klotz et al., 2013). The
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binding with these G protein-coupled receptors activates the subunit of the
heterotrimeric G protein and then triggers various secondary messaging systems and
corresponding cytoplasmic signaling transductions.
The pre-myograph incubation with EXT altered the contractile capacity in a
manner similar with previous studies. Using a bovine lateral saphenous vein model, Klotz
et al. (2012) found DOI (5HT2A receptor agonist) induced vessel contractile intensities
were 35% lower in high endophyte-infested tall fescue than in low endophyte-infested
tall fescue, whereas 5CT (5HT7 receptor agonist) produced greater (37%) contractile
intensities in high endophyte-infested tall fescue. Therefore, they indicated that chronic
exposure to ergot alkaloids through grazing endophyte-infested tall fescue altered the
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vasoconstriction via serotonergic receptors, but in different manners. In a subsequent
study (Klotz et al., 2013) they reported a suppression of the contractile response to
ergovaline and 5HT in steers grazing Kentucky-31 tall fescue infected with wild-type
endophyte. What’s more, Egert et al. (2014) showed the similar observation of reduced
contractile response to ergotamine in mesenteric vasculature of steers exposed with
endophyte-infected tall fescue seed. Taken together, it is possible that the EXT pretreatment might have reduced the vasoconstriction to ergotamine via altering the
potential biogenic amine receptor populations and activities, for example, the
antagonistic effects of ergot alkaloids to certain 5HT receptors have been shown
previously (Oliver et al., 1993; Pertz and Eich, 1999; Schoning et al., 2001). Although the
exact mechanisms are unknown, it is possible these alterations are mediated by the
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downreulation of gene transcription associated with secondary messaging pathways of G
protein-coupled receptors by ergot alkaloids (Maurer, 1981).
What’s more, many in vitro bioassays have proposed, in various vessel types and
in many different species, the binding of ergovaline and receptor was irreversible, or the
dissociation from the receptor was very slow (Dyer, 1993; Schoning et al., 2001; Klotz et
al., 2007; Pesqueira et al., 2014). Likewise, the bioaccumulation effect was reported in
bovine lateral saphenous veins after repetitive exposure of ergovaline in vitro (Klotz et al.,
2009). These findings may explain the differences of contractile response to initial
ergotamine addition (5 × 10-9 M) between mesenteric artery incubated with or without
endophyte-infected tall fescue seed extract. It is possible that during the two hour preincubation with endophyte-infected tall fescue seed extract, the corresponding receptors
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have been irreversibly bound by ergot alkaloids (mainly 1 × 10-6 M ergovaline) present in
the endophyte-infected tall fescue seed extract. This speculation was further validated by
the observation that the initial contractile response to ergotamine by EXT (containing 1 ×
10-6 M ergovaline) incubated mesenteric artery was numerically similar to 1 × 10 -6 M
ergotamine induced contractile response of mesenteric artery without EXT incubation. It
has been demonstrated that ergotamine and ergovaline are both potent vasoconstrictor
inducing similar contractile responses (Klotz et al., 2007).
In the present study, formononetin and biochanin A failed to offset the mesenteric
vasculature contraction induced by ergotamine. As discussed earlier in this section,
numerous studies have shown the vasodilative effect of isoflavones and their metabolites
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in different vessel types. Pretreatment with formononetin (30 and 50 μM) antagonized
contractile responses of rat thoracic aortas to norepinephrine in a noncompetitive
manner (Zhao et al., 2012). Sun et al. (2011) hypothesized that pre-incubation with
formononetin (30 and 100 μM) depressed the contraction of rat mesenteric artery to
phenylephrine and 5-HT, and similarly, depression was not observed when formononetin
at 10 μM. Again, the 1 μM formononetin and biochanin A in the present study were
possibly not in high enough concentrations to elicit vasorelaxations. Other evidence of
the chronic antihypertensive effect of formononetin has been reported based on male
spontaneously hypertensive rats (SHR) (Sun et al., 2013). They found that the
vasoconstriction of mesenteric artery segments induced by phenylephrine or 5-HT was
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reduced in formononetin (50 mg/kg per day) orally administrated SHR. What’s more, the
expression of α1-adrenoceptors and 5-HT2A/1B receptors in mesenteric artery of
formononetin treated SHR decreased (Sun et al., 2013). Even though there might be some

species differences between bovine and SHR, the two hour pre-myograph incubation with
formononetin or biochanin A in the present study may be not long enough to trigger
certain consequences.

With EXT in the pretreatment media, formononetin and biochanin A increased the
contractile response of mesenteric artery at several ergotamine concentrations. This has
provided the first evidence that the isoflavones, formononetin and biochanin A have
potential to alleviate the inhibitory effect of ergot alkaloids. However, current knowledge
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from ergot alkaloids and isoflavones are unable to explain this phenomenon, so more
investigations on their interaction are needed.
In conclusion, this study indicated that a pre-myograph incubation with
formononetin, biochanin A at 1 × 10-6 M and their combination did not affect the
contractile response to ergotamine in mesenteric vasculature. The pre-myograph
incubation of mesenteric vasculature with endophyte-infected tall fescue seed extract
(equivalent to 1 × 10-6 M ergovaline) reduced the vasoactivity of ergotamine. At higher
concentrations, formononetin and biochanin A may alleviate this reduction in vasoactivity
caused by prior exposure to ergot alkaloids. However, no current data are available to
fully support this observation, and future investigations are necessary to understand the
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mechanism behind the interaction of ergot alkaloids and isoflavone.
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